> Print and Download Article

Imagine sitting across from someone you’ve known for decades. You begin talking about familiar people, places, and experiences, only to realize that the person sitting in front of you no longer remembers some of those shared moments.

For millions of families, this is not an imaginary situation. It is part of everyday life.

Dementia can gradually take away a person’s ability to remember, communicate, make decisions, manage finances, prepare meals, and eventually perform basic daily activities.

For family members, the experience can be emotionally devastating.

A husband may find himself caring for a wife who no longer recognizes him. An adult daughter may become responsible for a mother who once managed an entire household. A family may spend years navigating medical appointments, behavioral changes, financial pressures, and the emotional burden of watching someone they love progressively lose independence.

According to the Alzheimer’s Association, approximately 12.7 million Americans provided unpaid care for people living with Alzheimer’s disease or other dementias in 2025. These caregivers provided an estimated 19.6 billion hours of care, valued at more than $446 billion [1].

These figures represent far more than an economic burden. They represent lost sleep, interrupted careers, emotional stress, and families whose lives have changed.

But there is another part of this story that deserves greater attention: What happens in the brain years before dementia is diagnosed?

And are there biological factors we could be paying closer attention to long before someone experiences noticeable memory problems?

Those questions helped motivate my interviews with 28 individuals diagnosed with dementia.

Understanding Dementia and Its Four Major Forms

One of the first things people should understand is that dementia is not a single disease.

Dementia is a general term describing a decline in memory, thinking, behavior, language, or other cognitive abilities severe enough to interfere with daily life.

Several different diseases can cause dementia.

Alzheimer’s Disease

Alzheimer’s is the most common cause of dementia, accounting for approximately 60%–80% of cases.

It is characterized by biological changes that include the accumulation of amyloid-beta proteins and abnormal tau proteins in the brain.

Over time, these changes contribute to nerve-cell dysfunction, loss of connections between brain cells, and progressive cognitive impairment.

Memory difficulties are often among the earliest noticeable symptoms, although Alzheimer’s can also affect language, judgment, orientation, and behavior.

Vascular Dementia

Vascular dementia develops when disease or damage affecting the brain’s blood vessels interferes with normal brain function.

This may involve strokes, small-vessel disease, or other conditions that damage the brain’s circulation.

High blood pressure, diabetes, smoking, and other cardiovascular risk factors are particularly relevant to vascular brain injury.

Some individuals develop cognitive problems after a recognized stroke, while others experience a more gradual decline associated with damage to smaller blood vessels.

Lewy Body Dementia

Lewy body dementia is associated with abnormal deposits of a protein called alpha-synuclein inside nerve cells.

Symptoms may include fluctuating attention, visual hallucinations, movement difficulties, and disturbances during rapid eye movement (REM) sleep.

Unlike typical Alzheimer’s disease, memory loss may not be the most prominent early symptom.

Frontotemporal Dementia

Frontotemporal dementia primarily affects the frontal and temporal regions of the brain, which are important for behavior, personality, decision-making, and language.

It can develop before age 65 and may initially be mistaken for a psychiatric or behavioral condition.

A person may experience major personality changes, impaired judgment, or difficulty speaking before significant memory loss becomes apparent.

Importantly, some people have mixed dementia, meaning more than one disease process contributes to their cognitive impairment.

Although these conditions have different underlying mechanisms, inflammation, vascular health, metabolism, and cellular function remain important areas of research.

What I Learned from Interviewing 28 People

Over the course of my interviews, I spoke with 28 individuals who reported having received a diagnosis of Alzheimer’s disease or another form of dementia.

My goal was to better understand their experiences, health histories, and awareness of potentially relevant biological factors.

The participants ranged in age from 59 to 79, with an average age of 68.

Of the 28 individuals:

• • 21 (75%) reported an Alzheimer’s disease diagnosis.
  • 4 (14.3%) had vascular dementia.
  • 2 (7.1%) had frontotemporal dementia.
  • 1 (3.6%) had Lewy body dementia.

Twenty-three were women, representing 82.1% of the interviewees, while five were men.

During these conversations, I also learned that several participants had experienced other health problems, including high blood pressure, elevated low-density lipoprotein (LDL) cholesterol, leg swelling, and transient ischemic attacks (TIAs), commonly called mini strokes.

These observations were interesting because cardiovascular and metabolic conditions have been associated with cognitive impairment in published research.

However, I want to be clear about an important distinction.

My 28 interviews are personal, exploratory observations—not a controlled clinical trial or a population-representative scientific study. They cannot establish what caused any participant’s dementia, determine the prevalence of a risk factor, or demonstrate that a particular intervention would prevent the disease.

Nevertheless, the conversations raised questions that I believe deserve further attention.

One observation in particular caught my attention: Not one of the 28 individuals was familiar with the At-Home Cellular Health Test (AKA BalanceTest) or understood the potential relevance of the omega-6 to omega-3 fatty-acid ratio to cognitive health.

I will return to that observation later in this article.

Alzheimer’s Disease Is Becoming a Growing Public Health Crisis

Alzheimer’s disease is not a normal or inevitable part of aging.

It is a major public health challenge, and the number of people affected continues to increase.

According to the Alzheimer’s Association’s 2026 Alzheimer’s Disease Facts and Figures report, approximately 7.4 million Americans aged 65 and older are living with Alzheimer’s dementia [1].

Without major breakthroughs in prevention or treatment, that number is projected to reach 13.8 million by 2060.

This projected growth is largely driven by population aging, particularly as more Americans reach the age groups at greatest risk.

However, the numbers become even more concerning when we examine the impact on families and the healthcare system.

In 2026, the estimated annual cost of health care, long-term care, and hospice services for Americans aged 65 and older living with dementia is approximately $409 billion [1].

These expenses include medical care, long-term care services, and other support that families may struggle to afford.

Alzheimer’s also affects people differently depending on their age, overall health, socioeconomic circumstances, and access to medical care.

The growing number of people affected means that we must pay greater attention not only to treatment after diagnosis but also to identifying and addressing modifiable risk factors throughout life.

We should not wait until someone begins forgetting familiar names or struggling with everyday tasks before having serious conversations about brain health.

Why Women Are Disproportionately Affected

One finding from my interviews was especially noticeable: 23 of the 28 individuals were women.

That represents 82.1% of the people I interviewed.

Although this small, nonrandom group cannot tell us how frequently Alzheimer’s occurs in women compared with men, the broader scientific literature confirms that women carry a disproportionate share of the Alzheimer’s burden.

According to the Alzheimer’s Association, nearly two-thirds of Americans living with Alzheimer’s dementia are women [1].

The estimated lifetime risk of Alzheimer’s dementia beginning at age 45 is approximately one in five for women, compared with one in ten for men.

Why?

One important explanation is longevity. Women generally live longer than men, and advancing age remains the strongest risk factor for Alzheimer’s disease.

However, longevity may not be the entire explanation.

Researchers are investigating the roles of reproductive aging, hormonal changes, genetics, cardiovascular health, immune function, and social determinants of health.

The relationship between menopause, estrogen changes, and Alzheimer’s disease is an especially active area of investigation. Nevertheless, it would be premature to conclude that menopause itself causes Alzheimer’s or that hormone therapy prevents it.

For women, protecting brain health deserves attention long before the traditional retirement years.

That includes maintaining healthy blood pressure, managing diabetes risk, remaining physically active, and paying attention to metabolic and cardiovascular health.

Alzheimer’s Disease and Dementia: Why Race and Ethnicity Matter

Another important aspect of the growing dementia crisis is that Alzheimer’s disease and related dementias do not affect all racial and ethnic populations equally.

According to the Alzheimer’s Association’s 2026 report, older Black Americans are approximately twice as likely to have Alzheimer’s disease or another dementia compared with older White Americans. Older Hispanic Americans are approximately 1.5 times as likely [1].

One population-based study cited in the report estimated that Alzheimer’s dementia affected approximately 19% of Black adults, 14% of Hispanic adults, and 10% of White adults aged 65 and older.

These differences deserve attention.

But why do they exist?

Researchers believe the explanations involve multiple factors, including cardiovascular and metabolic health, socioeconomic conditions, educational opportunities, environmental exposures, and access to quality healthcare.

The Connection to High Blood Pressure and Diabetes

Black and Hispanic communities experience disproportionate burdens of certain conditions associated with increased dementia risk, including high blood pressure and type 2 diabetes.

High blood pressure can damage the blood vessels supplying the brain, while diabetes and insulin resistance can contribute to vascular injury and metabolic dysfunction.

These are among the reasons I continue emphasizing that brain health and metabolic health are closely connected.

However, race and ethnicity should not be treated as biological explanations by themselves. Many of the observed differences in dementia risk are influenced by modifiable health conditions and the social and environmental circumstances people experience throughout their lives.

The Problem of Delayed Diagnosis

There is another concerning aspect of these disparities.

Research suggests that Black and Hispanic Americans living with dementia are less likely to receive a timely diagnosis than White Americans.

A 2026 study published in the Journal of General Internal Medicine examined racial and ethnic disparities in timely dementia diagnosis [2].

Researchers found that Black and Hispanic older adults experienced disparities in timely diagnosis, with individual and neighborhood characteristics helping explain some of these differences.

This means that some individuals may already be experiencing significant cognitive difficulties before receiving appropriate medical evaluation.

Delayed diagnosis can also delay access to treatment, support services, and opportunities for families to prepare for future care needs.

Why This Matters

Whether someone is Black, Hispanic, White, Asian, Native American, or from another racial or ethnic background, brain health deserves attention.

The available evidence is strongest for comparisons among Black, Hispanic, and White older adults. More research is needed to understand the different experiences of other racial and ethnic populations.

The message should not be that someone’s ethnicity determines whether they will develop Alzheimer’s disease.

The message is that we need greater awareness, earlier recognition of cognitive changes, better management of cardiovascular and metabolic risk factors, and more equitable access to healthcare.

And as scientists continue investigating the relationship between fatty-acid balance and cognitive health, I believe these research questions deserve attention across all communities.

Dementia Before Age 65: A Concern We Cannot Ignore

Many people associate dementia with individuals in their late seventies, eighties, or nineties.

But dementia can develop much earlier.

When symptoms begin before age 65, the condition is commonly described as young-onset dementia.

The youngest individual in my interviews was 59 years old.

This matters because dementia during working age can create challenges that differ from those experienced by older adults.

Someone in their fifties or early sixties may still be raising children, supporting a household, managing a business, or caring for aging parents.

A dementia diagnosis can affect employment, financial security, relationships, and independence.

And research suggests that this is a growing public health concern.

Blue Cross Blue Shield: Diagnoses Tripled in Four Years

In February 2020, the Blue Cross Blue Shield Association published a report examining early-onset dementia and Alzheimer’s disease among commercially insured Americans [3].

The findings were striking.

Researchers analyzed health insurance claims covering more than 48 million members and examined recorded diagnoses among adults ages 30 to 64 between 2013 and 2017.

During that four-year period, the recorded diagnosis rate increased by 200%.

To put that into perspective, a 200% increase means the rate tripled.

In 2013, approximately 4.2 out of every 10,000 insured adults ages 30 to 64 had a recorded diagnosis.

By 2017, that figure had increased to 12.6 per 10,000.

The increases were especially pronounced among younger age groups:

• • Ages 30–44: 373% increase.
  • Ages 45–54: 311% increase.
  • Ages 55–64: 143% increase.

The report estimated that approximately 131,000 commercially insured Americans ages 30 to 64 were living with early-onset dementia or Alzheimer’s disease in 2017.

And consider this: The average age of affected individuals was just 49.

Women represented 58% of those diagnosed.

These findings deserve attention, but they require careful interpretation. The report measured the proportion of insured individuals with recorded diagnoses, not the number of people newly developing dementia each year. The authors acknowledged that much of the increase could reflect people remaining in the insured population after diagnosis, rather than a comparable increase in new cases.

Nevertheless, the report is an important reminder that dementia is not exclusively a disease of advanced age.

Brain health deserves attention in our thirties, forties, and fifties—not simply after retirement.

A 2025 Global Study Found the Burden Has More Than Doubled

Another important study, published in the European Journal of Neurology in 2025, examined the global burden of early-onset Alzheimer’s disease and other dementias among adults ages 40–64 [4].

Researchers analyzed data covering 1990 through 2021.

Their findings showed that the estimated number of people worldwide living with early-onset Alzheimer’s disease or another dementia increased from approximately 3.67 million in 1990 to 7.75 million in 2021.

That represents an increase of approximately 111%.

The estimated annual number of new cases also increased, from approximately 630,000 in 1990 to 1.38 million in 2021.

However, an important scientific distinction must be made: An increase in the total number of people living with a condition does not necessarily mean an equivalent increase in each person’s probability of developing it.

Population growth, aging within the under-65 age range, diagnostic practices, and changes in underlying risk can all influence the numbers.

In fact, the same analysis found a much smaller increase in age-standardized prevalence than in the total number of cases [4].

 

What These Two Studies Tell Us

The Blue Cross Blue Shield report and the 2025 global analysis examined different populations, time periods, and measures.

The Blue Cross report focused on recorded diagnoses among commercially insured Americans ages 30–64 between 2013 and 2017.

The global study examined modeled estimates of dementia prevalence and incidence among adults ages 40–64 from 1990 through 2021.

Although they cannot be directly compared, both highlight the substantial burden of dementia among adults younger than 65.

And that raises an important question:

What are we doing to help people protect their brain health decades before they might develop cognitive symptoms?

The Connection Between Metabolic Health and Brain Health

One of the reasons I became interested in the relationship between dementia and overall health is that the brain does not operate independently of the rest of the body.

The brain depends on healthy circulation, adequate nutrients, stable energy availability, functioning nerve cells, and effective communication between cells.

Conditions that affect cardiovascular and metabolic health may also influence cognitive function.

In 2024, the Lancet Commission on dementia prevention, intervention, and care identified 14 potentially modifiable risk factors associated with dementia [5].

These included high blood pressure, diabetes, obesity, physical inactivity, smoking, high low-density lipoprotein cholesterol, hearing impairment, untreated vision loss, and other factors.

The commission estimated that approximately 45% of dementia cases could potentially be prevented or delayed if these risk factors were effectively addressed at the population level.

That is a model-based estimate, not a guarantee that any individual can prevent dementia.

Type 2 Diabetes and Insulin Resistance

Insulin is a hormone that helps regulate blood glucose and participates in numerous metabolic processes.

Insulin resistance occurs when cells respond less effectively to insulin, often requiring the body to produce more of it to maintain glucose regulation.

Type 2 diabetes and impaired glucose regulation have been associated with increased dementia risk.

Researchers are investigating several possible mechanisms, including vascular injury, chronic inflammation, altered cellular energy metabolism, and changes in insulin signaling.

Although Alzheimer’s disease is sometimes informally called type 3 diabetes, this is not an accepted clinical diagnosis or a complete explanation of the disease.

High Blood Pressure

High blood pressure can damage blood vessels throughout the body, including those supplying the brain.

Over time, vascular injury may contribute to stroke, small-vessel disease, and cognitive impairment.

Managing blood pressure is therefore an important part of protecting both cardiovascular and brain health.

Excess Body Fat and Weight Loss

Excess body fat, particularly when associated with insulin resistance and other metabolic abnormalities, may contribute to cardiovascular and inflammatory processes linked to dementia risk.

However, the relationship between body weight and dementia changes across the lifespan.

Midlife obesity is a recognized risk factor, whereas unintentional weight loss later in life may sometimes be an early sign of underlying disease.

This is why healthy weight management should focus on preserving skeletal muscle, meeting nutritional needs, and improving metabolic health—not simply making the number on the scale smaller.

Inflammation

Inflammation is a normal biological process that helps the body respond to injury and infection.

However, persistent or poorly regulated inflammation can contribute to tissue dysfunction.

Within the brain, immune cells called microglia help maintain the neural environment. Abnormal or prolonged inflammatory responses may participate in the progression of neurodegenerative disease.

This brings us to another important area of research: the fatty acids that help regulate cell membranes and participate in the production of inflammatory and inflammation-resolving signaling molecules.

The 2026 Study: Omega-6, Omega-3, and Dementia Progression

This is where the scientific discussion becomes particularly interesting.

In June 2026, Andrade and colleagues published a study in Alzheimer’s & Dementia, the peer-reviewed journal of the Alzheimer’s Association, titled:

“Prediction of Cognitive Outcome and Progression to Dementia Using ω6-PUFA/ω3-PUFA Ratio” [6].

The researchers examined data from two major groups: the German Study on Aging, Cognition, and Dementia (AgeCoDe), involving 3,327 participants, and the Multidomain Alzheimer Preventive Trial (MAPT), involving 1,679 participants.

Combined, these cohorts included 5,006 participants.

The investigators examined whether the balance between omega-6 and omega-3 polyunsaturated fatty acids could help predict cognitive outcomes and progression to Alzheimer’s-type dementia.

Their findings deserve attention.

A Higher Ratio Was Associated with Greater Dementia Risk

The researchers found that a higher omega-6 to omega-3 ratio was associated with a greater likelihood of progression to Alzheimer’s-type dementia.

Importantly, the ratio provided predictive information beyond omega-3 measurements alone.

A Higher Baseline Ratio Predicted Faster Cognitive Decline

Individuals with less favorable fatty-acid ratios at baseline tended to experience faster cognitive decline.

This finding suggests that the relationship between different fatty acids may provide useful information about cognitive health.

Improvements in the Ratio Were Associated with Better Cognitive Outcomes

In longitudinal analyses, reductions in an unfavorable ratio were associated with slower cognitive decline.

This is particularly interesting because it raises the possibility that fatty-acid balance could become a useful target for future dietary intervention studies.

The Researchers Did Not Establish Causation

This is an essential scientific limitation.

The investigators also conducted genetic analyses, which did not establish a causal relationship between the fatty-acid measures and progression to dementia.

Therefore, the study does not prove that lowering the omega-6 to omega-3 ratio prevents Alzheimer’s disease, reverses cognitive decline, or treats dementia.

Nor does it establish that taking an omega-3 supplement will produce the same cognitive outcomes.

Nevertheless, the study offers an important direction for further research.

The major scientific takeaway is that fatty-acid balance may provide information about cognitive outcomes that is not captured by measuring omega-3 fatty acids alone.

That is an observation worth investigating.

Understanding the Omega-6 to Omega-3 Ratio

To understand why this research matters, we first need to understand two families of fats: omega-6 and omega-3 fatty acids.

Both are important components of a healthy diet and normal human physiology.

Omega-6 Fatty Acids

Omega-6 fatty acids participate in cell structure, growth, immune responses, and numerous signaling processes.

Linoleic acid is an essential omega-6 fatty acid, meaning the body cannot manufacture it and must obtain it from food.

Another omega-6 fatty acid, arachidonic acid (AA), participates in the production of signaling molecules involved in inflammation and other physiological processes.

However, omega-6 fatty acids are not inherently harmful, and inflammation itself is not always harmful.

Omega-3 Fatty Acids

Omega-3 fatty acids are also important for normal health.

Two marine omega-3 fatty acids deserve particular attention.

Eicosapentaenoic acid (EPA) participates in cellular signaling and is a precursor to certain inflammation-resolving mediators.

Docosahexaenoic acid (DHA) is a major structural component of neuronal membranes and plays an important role in normal brain and retinal function.

DHA is particularly relevant to the physical structure and function of brain-cell membranes.

Why the Balance Matters

Imagine a cell membrane as a flexible outer boundary that helps regulate communication between the cell and its environment.

The types of fatty acids incorporated into that membrane can influence its physical properties and certain cellular functions.

Omega-6 and omega-3 fatty acids also participate in interconnected metabolic pathways.

For example, arachidonic acid and EPA can serve as precursors to different signaling molecules.

However, the biology is more complicated than saying omega-6 causes inflammation and omega-3 stops it. Both families have necessary functions, and their effects depend on the specific fatty acids, tissues, metabolic conditions, and signaling pathways involved.

The 2026 study is interesting because it examined the relationship between these fatty-acid families rather than considering omega-3 alone [6].

That said, researchers have not established a universally accepted omega-6 to omega-3 ratio that prevents dementia.

Nor should findings involving specific blood fatty-acid ratios automatically be applied to every commercially available testing method.

The Health Blind Spot: What None of My 28 Interviewees Knew

Now we return to the observation that originally caught my attention.

Of the 28 individuals I interviewed, not one was familiar with the BalanceTest.

Not one understood the potential relationship between omega-6 to omega-3 fatty-acid balance and cognitive health.

All 28 were unaware of this area of emerging research.

I find that concerning—not because the test has been proven to prevent Alzheimer’s, but because it illustrates how much information about nutrition, cellular biology, and emerging biomarkers may be unfamiliar to the public.

The Alzheimer’s Association’s 2026 report reinforces the broader awareness problem.

In its special report on brain health, 99% of surveyed Americans considered brain health at least as important as physical health, yet only 9% reported knowing a lot about how to maintain it [1].

That is a remarkable gap between concern and understanding.

I often encounter people who know their cholesterol numbers, blood pressure, blood glucose, and body weight, yet have never heard of the omega-6 to omega-3 ratio.

My personal impression is that awareness of this particular measure is extremely limited.

I suspect the overwhelming majority of adults have never had their fatty-acid balance measured, but I cannot substantiate a precise figure such as 99% without a representative survey.

The larger point remains: People cannot make informed decisions about a health measure they have never heard of.

And as emerging research continues to investigate fatty-acid balance and cognitive outcomes, I believe the public deserves access to clear, scientifically accurate information about what is known, what remains uncertain, and what future research may reveal.

One additional clarification is important: My interviewees’ lack of awareness does not demonstrate that all 28 had an abnormal fatty-acid ratio. Establishing that would require actual laboratory results obtained using a defined method and interpreted against appropriate reference values.

The Importance of Testing and Early Action

Throughout my career, I have emphasized the importance of objective health measurements.

My philosophy is simple:

Test. Don’t Guess.

I encourage people to understand their metabolic and cardiovascular health through appropriate measurements rather than relying entirely on how they feel.

For example, blood pressure can be elevated without obvious symptoms. Insulin resistance can develop long before a person receives a diagnosis of type 2 diabetes.

Similarly, biological changes associated with Alzheimer’s disease may begin many years before noticeable cognitive symptoms develop.

This does not mean every available laboratory test can diagnose or predict Alzheimer’s.

The At-Home Cellular Health Test, also known as the BalanceTest, is designed to provide information about fatty-acid status, including omega-6 and omega-3 measurements.

It is not an Alzheimer’s diagnostic test, and there is currently insufficient clinical evidence to recommend it as a validated method for determining an individual’s dementia risk.

However, for people interested in understanding their nutritional fatty-acid status, such testing may provide information that can be discussed with a qualified healthcare professional.

Likewise, increasing EPA and DHA intake through food or appropriate supplementation can change certain fatty-acid biomarkers, but improving those biomarkers should not be presented as proof of preventing or treating dementia.

A better biomarker result and a better clinical outcome are not necessarily the same thing.

This distinction is especially important when translating promising research into recommendations for the public.

What You Can Do to Support Brain Health

Although scientists continue investigating the causes and mechanisms of dementia, there are established steps people can take to support overall brain health.

The 2024 Lancet Commission provides a useful framework for addressing modifiable dementia risk factors [5].

These include maintaining healthy blood pressure, managing diabetes, remaining physically active, avoiding smoking, addressing hearing and vision impairment, and reducing other cardiovascular risks.

I encourage adults to discuss the following with their healthcare professionals:

• • Cardiovascular health: Know your blood pressure and address elevated LDL cholesterol and other vascular risk factors.
  • Metabolic health: Monitor blood glucose and glycated hemoglobin (HbA1c), and address insulin resistance or diabetes when present.
  • Nutrition: Eat a varied, nutritionally adequate diet that supports cardiovascular and metabolic health, including appropriate sources of essential fatty acids.
  • Physical activity: Incorporate regular aerobic activity and resistance exercise, adapted to individual ability.
  • Sleep and social engagement: Address sleep disorders and maintain meaningful social and mentally stimulating activities.
  • Cognitive symptoms: Seek medical evaluation for persistent or progressive memory, language, behavioral, or thinking changes.

People with diagnosed dementia should continue their prescribed treatment and specialist care.

Anyone experiencing sudden confusion, weakness, difficulty speaking, or other possible stroke symptoms should seek emergency medical attention.

The goal is not to suggest that dementia can always be prevented.

It is to recognize that there are meaningful opportunities to improve health and potentially reduce or delay some dementia risk throughout life.

Final Thoughts: Knowledge That Changes Lives

When I began interviewing these 28 individuals, I wanted to better understand the people behind the diagnoses.

I wanted to learn about their experiences, their health histories, and the challenges they were facing.

What emerged was a collection of personal stories that reinforced how devastating dementia can be—not only for the person diagnosed but also for the people who love and care for them.

The interviews also strengthened my interest in the connections between cardiovascular health, metabolism, inflammation, nutrition, and brain function.

And they raised an important question about awareness.

How many people are living their lives without knowing that researchers are investigating relationships between fatty-acid balance and cognitive health?

The 2026 study by Andrade and colleagues provides an intriguing reason to continue asking that question.

It does not prove that fatty-acid imbalance causes Alzheimer’s. It does not establish that improving the ratio will prevent dementia.

But it does suggest that the relationship between omega-6 and omega-3 fatty acids may be more relevant to cognitive outcomes than previously appreciated.

I believe this is a subject deserving greater public awareness and further clinical research.

My hope is that more people will begin taking brain health seriously long before noticeable memory problems develop.

If you would like to learn more about cellular health, fatty-acid testing, and the research discussed in this article, you can contact me at robert@dietfreelife.com.

The more we learn about our health, the better equipped we are to make informed decisions.

Knowledge That Changes Lives.

References

1. 1. Alzheimer’s Association. (2026). 2026 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia, 22, e71345. https://doi.org/10.1002/alz.71345
   2. Qian, Y., Li, F., & Chen, X. (2026). Associations of individual- and neighborhood-level factors with racial and ethnic disparities in timely dementia diagnosis. Journal of General Internal Medicine, 41, 3779–3789. https://doi.org/10.1007/s11606-026-10420-8
   3. Blue Cross Blue Shield Association. (2020). Early-onset dementia and Alzheimer’s rates grow for younger Americans. The Health of America Report. https://www.bcbs.com/media/pdf/HOA-Early-Onset-Dementia-Alzheimers_2020.pdf
   4. Zhang, Z., Han, S., Zhu, H., Wang, Q., Cheng, S., Han, Y., Li, F., & Guo, J. (2025). Global, regional, and national burden of early-onset Alzheimer’s disease and other dementias in young adults aged 40–64 years, 1990–2021: A population-based study. European Journal of Neurology, 32, e70116. https://doi.org/10.1111/ene.70116
   5. Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., Fox, N. C., Ferri, C. P., Gitlin, L. N., Howard, R., Kales, H. C., Kivimäki, M., Larson, E. B., Nakasujja, N., Rockwood, K., et al. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet, 404(10452), 572–628. https://doi.org/10.1016/S0140-6736(24)01296-0
   6. Andrade, V., Kleineidam, L., Wagner-Thelen, H., Ballarini, T., Campos-Martin, R., Martino-Adami, P., Tripathi, K. P., Guyonnet, S., Vellas, B., Scherer, M., Maier, W., Pentzek, M., Schmid, M., Riedel-Heller, S., Weyerer, S., Bickel, H., Wiese, B., Egert, S., Wagner, M., & Ramírez, A. (2026). Prediction of cognitive outcome and progression to dementia using ω6-PUFA/ω3-PUFA ratio. Alzheimer’s & Dementia, 22(6), e71590. https://doi.org/10.1002/alz.71590

__________
Robert Ferguson is a California- and Florida-based single father of two daughters, clinical nutritionist, Omega Balancing Coach™, researcher, best-selling author, speaker, podcast and television host, health advisor, NAACP Image Award Nominee, creator of the Diet Free Life methodology, and Chief Nutrition Officer for iCoura Health. He also serves on the Presidential Task Force on Obesity for the National Medical Association and the Health and Product Advisory Board for Zinzino, Inc.

🗓️ Schedule a FREE consultation with Robert Ferguson about becoming a client: SCHEDULE FREE CONSULTATION

👉🏽 To order the BalanceOil+ with the BalanceTEST, > CLICK HERE

👉🏽 Watch a free online presentation on the BalanceOil+ and the BalanceTEST: WATCH NOW.